No connection

Search Results

BDRX vs SXTC

BDRX
Biodexa Pharmaceuticals Plc
BEARISH
Price
$2.15
Market Cap
$1.8M
Sector
Healthcare
AI Confidence
95%
SXTC
China SXT Pharmaceuticals, Inc.
BEARISH
Price
$2.06
Market Cap
$2.0M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BDRX
--
SXTC
--
Forward P/E
BDRX
--
SXTC
--
P/B Ratio
BDRX
0.09
SXTC
0.08
P/S Ratio
BDRX
--
SXTC
1.28
EV/EBITDA
BDRX
-15012.8
SXTC
2.22

Profitability

Gross Margin
BDRX
0.0%
SXTC
21.74%
Operating Margin
BDRX
0.0%
SXTC
-1011.69%
Profit Margin
BDRX
0.0%
SXTC
0.0%
ROE
BDRX
-61.77%
SXTC
-50.3%
ROA
BDRX
-39.04%
SXTC
-18.27%

Growth

Revenue Growth
BDRX
--
SXTC
-24.5%
Earnings Growth
BDRX
--
SXTC
--

Financial Health

Debt/Equity
BDRX
0.04
SXTC
0.06
Current Ratio
BDRX
3.63
SXTC
4.37
Quick Ratio
BDRX
3.63
SXTC
4.04

Dividends

Dividend Yield
BDRX
--
SXTC
--
Payout Ratio
BDRX
0.0%
SXTC
0.0%

AI Verdict

BDRX BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.

Strengths
Strong liquidity position with current and quick ratios of 3.63, indicating ability to cover short-term liabilities.
Low debt/equity ratio of 0.04, reflecting minimal leverage risk.
Two out of three recent quarters beat earnings estimates, showing some operational predictability.
Risks
Piotroski F-Score of 2/9 indicates very weak financial health and high risk of continued deterioration.
No Altman Z-Score available, but negative ROE (-61.77%) and ROA (-39.04%) suggest high bankruptcy risk.
Profitability metrics are entirely negative: 0% gross, operating, and profit margins.
SXTC BEARISH

SXTC presents a profile of a company in a catastrophic financial death spiral, despite a Piotroski F-Score of 5/9 suggesting baseline stability. The stock has collapsed from a 52-week high of $1047.00 to $2.06, representing a near-total loss of shareholder value. While the balance sheet shows low debt and high liquidity (Current Ratio 4.37), the operational reality is dire with an operating margin of -1011.69% and declining revenues. The extreme Price-to-Book ratio of 0.08 indicates the market has almost entirely discounted the company's asset value.

Strengths
Very low Debt/Equity ratio (0.06)
Strong short-term liquidity (Current Ratio 4.37)
Piotroski F-Score of 5/9 indicates stable accounting health
Risks
Catastrophic operating losses (Operating Margin -1011.69%)
Severe revenue contraction (-24.50% YoY)
Extreme price volatility and historical collapse (-98.7% 1Y return)

Compare Another Pair

BDRX vs SXTC: Head-to-Head Comparison

This page compares Biodexa Pharmaceuticals Plc (BDRX) and China SXT Pharmaceuticals, Inc. (SXTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile